Bcl-2抑制剂在淋巴肿瘤治疗中的应用  

Application of a Bcl-2 protein inhibitor in the treatment of lymphoma

作　　者：李茹 邱录贵 易树华 Ru Li;Lugui Qiu;Shuhua Yi(Institute of Hematology&Blood Diseases Hospital,National Clinical Research Center for Blood Diseases,State Key Laboratory of Experimental Hematology,Tianjin 300020,China)

机构地区：[1]中国医学科学院血液病医院(中国医学科学院血液学研究所),国家血液系统疾病临床医学研究中心,实验血液学国家重点实验室,天津市300020

出　　处：《中国肿瘤临床》2021年第13期686-689,共4页Chinese Journal of Clinical Oncology

基　　金：国家自然科学基金项目(编号:81970187,81900203);中国医学科学院医学与健康科技创新工项目(编号:2019-I2M-2-009,CAMS-2017-I2M-1-005)资助。

摘　　要：Bcl-2家族在细胞凋亡的内源性途径中发挥至关重要的作用,其中Bcl-2蛋白属于抗凋亡蛋白,因此靶向Bcl-2蛋白的抑制剂可促进细胞凋亡,进而达到抗肿瘤目的。在临床上应用最为广泛的是venetoclax,在治疗慢性淋巴细胞白血病(chronic lymphocytic leukemia,CLL)中具有重要优势,其可克服17p-、IGHV未突变等多种不良预后因素。此外,在套细胞淋巴瘤(mantle cell lymphoma,MCL)、弥漫性大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)和滤泡性淋巴瘤(follicular lymphoma,FL)中均具有较好的治疗效果及安全性。The Bcl-2 family plays a crucial role in the endogenous pathway of apoptosis;the Bcl-2 protein is an apoptotic protein.Therefore,inhibitors targeting the Bcl-2 protein can promote cell apoptosis and be used to achieve antitumor goals.Venetoclax,the most widely used Bcl-2 inhibitor,has important effects,especially against chronic lymphocytic leukemia(CLL),and venetoclax administration can overcome some poor prognostic factors,such as unmutated IGHV and 17p deletions.In addition,it has therapeutic effects and a satisfactory safety profile for the treatment of mantle cell lymphoma(MCL),diffuse large B-cell lymphoma(DLBCL),and follicular lymphoma(FL).

关 键 词：BCL-2 蛋白抑制剂 venetoclax 淋巴肿瘤 慢性淋巴细胞白血病 

分 类 号：R733.1[医药卫生—肿瘤]